Chimeric antigen receptor (CAR) T cell therapies have been successful in treating leukemias and lymphomas and there are currently seven FDA-approved therapies that target B cells using CD19 and B cell maturation antigen (BCMA) as targets (1, 2). The gene discussed is TNFRSF17; the disease is lymphoma.